Moderna has announced the failure of its late-stage trial for the mRNA-1647 vaccine, designed to prevent cytomegalovirus (CMV) infection. The trial, which primarily targeted seronegative women...
Moderna has released updated data from a Phase 4 clinical trial demonstrating that its redesigned COVID-19 vaccine, known as mNEXSPIKE, significantly enhances immune response. The study...
Moderna has announced the production of its first Canadian-made doses of mRNA vaccines, marking a significant milestone in the company’s operations. The announcement was made by...
The average short interest in the S&P 500 Healthcare sector decreased in August 2023, indicating a slight easing of negative investor sentiment. According to recent data,...
